The news: A real-world study on Novo Nordisk’s obesity drug showed patients had significantly reduced “food noise,” which are persistent, unwanted thoughts about eating. Novo surveyed 550 US adults taking Wegovy for weight loss for at least four months.

Digging into the details: Patients on Novo’s GLP-1 medicine Wegovy reported less time thinking about food along with better mental health and healthier habits.

• Before starting Wegvoy, 62% of patients experienced constant thoughts about food, but that dropped to 16% while on the medicine.
• 60% said food noise had a negative effect on their lives before treatment, compared to 20% on treatment.
• Almost two-thirds (64%) saw improved mental health and 80% had healthier habits while taking the GLP-1.